Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies
Authors:
Open Access
- 1 February 2011
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 104 (3) , 399-406
Abstract
Optimum efficacy is the primary goal for any cancer therapy, and entails controlling tumour growth and prolonging survival as far as possible. The prognosis for patients with metastatic renal cell carcinoma (mRCC) has greatly improved with the introduction of targeted therapies. This review examines the development and efficacy of targeted agents for the management of mRCC, the challenges offered by their rapid emergence, and discusses how mRCC treatment may evolve in the future. Improvements in progression-free survival and overall survival rates, observed with targeted agents, indicate that it may now be possible to change mRCC from a rapidly fatal and largely untreatable condition into a chronic disease. The major challenges to further advances in targeted therapy for mRCC include overcoming drug resistance, identifying the most effective sequence or combination of targeted agents, optimising clinical trial design and managing the cost of treatment.Keywords
This publication has 57 references indexed in Scilit:
- Effects of HIF-1 and HIF2 on Growth and Metabolism of Clear-Cell Renal Cell Carcinoma 786-0 XenograftsJournal of Oncology, 2010
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid TumorsClinical Cancer Research, 2009
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation TrialJournal of Clinical Oncology, 2009
- Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2009
- Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2Journal of Biological Chemistry, 2008
- mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?British Journal of Cancer, 2008
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Estimates of the cancer incidence and mortality in Europe in 2006Annals of Oncology, 2007